{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:11025495",
      "entity_text" : "cholesterol",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0923" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "In regards to tocilizumab, despite initial concerns for worsened CV outcomes due to increases in total cholesterol levels, long-term follow-up studies show that rates of stroke and MI after tocilizumab treatment (mean duration of 2.4 years) are comparable to that of RA patients on MTX alone or in conjunction with placebo [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-07-28T16:07:59Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:56:14Z",
  "trigger" : "levels",
  "evidence" : [ "cholesterol levels" ],
  "pmc_id" : "7021876",
  "score" : 0
}